The most commonly reported ( @ % ) adverse events were diarrhoea ( dolutegravir @ -LSB- @ % -RSB- patients vs darunavir plus ritonavir @ -LSB- @ % -RSB- patients ) , nausea ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , and headache ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .